Ask about this productRelated genes to: MAGEA1 Blocking Peptide
- Gene:
- MAGEA1 NIH gene
- Name:
- MAGE family member A1
- Previous symbol:
- MAGE1
- Synonyms:
- MGC9326, CT1.1
- Chromosome:
- Xq28
- Locus Type:
- gene with protein product
- Date approved:
- 1994-04-04
- Date modifiied:
- 2017-04-21
Related products to: MAGEA1 Blocking Peptide
Related articles to: MAGEA1 Blocking Peptide
- Cryptorchidism is caused by a combination of environmental and genetic variables. This study aimed to identify cryptorchidism-associated susceptibility genes through bioinformatics approaches and validate their dynamic expression patterns in rat models, with the exploration of upstream transcriptional factor (TF) regulatory networks. - Source: PubMed
Publication date: 2026/03/17
Chen JianxunShen DanKong JianZhang YouboGe WenliangXian Hua - MAGE family member A1 (MAGEA1), a cancer‑testis antigen (CTA), is aberrantly expressed in several malignancies such as lung and liver cancers. However, its role in cervical cancer remains to be elucidated. The present study investigated the functional significance and therapeutic potential of MAGEA1 in cervical cancer using lentiviral short hairpin RNA‑mediated knockdown, a series of functional assays, RNA sequencing (RNA‑seq), and nude mouse xenograft models. It was found that MAGEA1 was upregulated in cervical cancer cells and its knockdown substantially suppressed cell proliferation, migration, invasion, and tumor growth. RNA‑seq analysis further revealed that MAGEA1 silencing altered pathways related to apoptosis, DNA repair, and metabolism. Moreover, MAGEA1 knockdown enhanced chemosensitivity, indicating a potential role in mediating drug resistance. Collectively, the findings identified MAGEA1 as a key oncogenic driver in cervical cancer and highlighted its promise as both a prognostic biomarker and a therapeutic target, offering novel avenues for personalized treatment strategies in cervical cancer. - Source: PubMed
Publication date: 2026/03/13
Kim AyoungKim JinaKwak WooriMo KyuminChoe SoohyunJeon MinyeongLee JisunYun Jun-WonYoon Hyunho - Hepatocellular carcinoma (HCC) accounts for approximately 90% of all primary liver cancers resulting in approximately 830,000 deaths in 2020, making HCC the sixth most common cancer globally. Several members of the Melanoma Antigen Gene (MAGE) family, such as MAGE-A1 and A3 genes of the MAGE I-A subfamily, are abnormally expressed in a variety of cancers including melanomas, colorectal cancer, non-small cell lung cancer, gliomas, HCC, prostate, and breast cancers. In addition, they have been linked to tumor stemness and, therefore, may predict therapeutic response and prognosis. - Source: PubMed
Publication date: 2026/01/22
Elgamal HodaElhammady DinaEl-Khair Salwa M AboEl-Badrawy AdelSamir AmrFarid KhaledEl Alfy Hatem - : We conducted the largest multinational review to date evaluating outcomes following radiotherapy for non-small cell lung carcinoma (NSCLC) patients with oligoprogressive disease (OPD) on immune checkpoint inhibitors (ICIs). : Patients with NSCLC irradiated to ≤5 progressive lesions while receiving ICIs between 2010 and 2023 were identified. We evaluated predictors of local control (LC), progression-free survival (PFS), and overall survival (OS). Patient demographics, disease characteristics, and survival were analyzed using the Wilcoxon test, Kaplan-Meier methods, and uni-/multivariate Cox models. : Out of 1178 treated patients, 103 eligible ones were included. The median OPD lesion was 1; the most common site was the lung (n = 33). The median LC of irradiated OPD lesions was not reached. Median PFS and OS were 6.90 (5.75-12.91) and 23.46 (17.54-37.16) months, respectively. Patient demographics, tumor pathological factors, number of OPD lesions, cumulative tumor volume, radiation modality, and OPD response to prior ICIs before radiation were not associated with these three outcomes. However, LC was associated with intermediate/high radiation doses ( = 0.005) and local response to radiation ( = 0.007). Improved PFS was associated with visceral OPD sites following radiation ( = 0.01). A favorable OS was associated with intermediate/high radiation doses ( = 0.01), local response to radiation ( = 0.006), and duration of last ICI before OPD ( = 0.03). : Promising outcomes were observed with ICI and radiation for visceral OPD at intermediate/high doses. Prolonged ICI use before OPD and local response to radiotherapy improved survival. These data can contribute towards guidance of multidisciplinary clinical decision-making for managing OPD in NSCLC patients receiving ICIs. - Source: PubMed
Publication date: 2025/12/25
Mahmood UmairJosephides EleniCoupe NicholasSmith DanielAhmad ShahreenAl-Salihi OmarMak Sze MChitnis MeenaliGeorgiou AlexandrosAjzensztejn DanielKarapanagiotou EleniHiggins Geoff SPanakis NikiSchoenfeld Jonathan DSkwarski Michael - : The androgen receptor (AR) is a ligand-dependent transcription factor of the nuclear steroid receptor superfamily, implicated in the pathogenesis of various solid tumors. The gene, located on chromosome Xq11-12, is accompanied by several X-linked genes that modulate expression and function, including , , and members of the melanoma antigen gene (MAGE) family (, , , ). While the AR has been investigated in multiple tumor types, its role in adult-type diffuse gliomas remains largely unexplored. Here, we characterized AR protein expression and the promoter methylation status of the AR and associated regulatory genes in adult-type diffuse gliomas. : A retrospective analysis was conducted on 50 patients with adult-type diffuse gliomas, including IDH-mutant gliomas (grades 2-4) and IDH-wildtype glioblastomas (GBMs), classified according to the 2021 WHO criteria. AR nuclear expression was assessed by immunohistochemistry (IHC). Methylation-specific PCR and quantitative DNA methylation analyses were employed to evaluate promoter methylation of the AR and selected co-regulatory genes. : AR nuclear positivity correlated significantly with male sex ( = 0.04) and higher tumor grade, with the highest expression in IDH-wildtype GBMs ( = 0.04). In IDH-mutant gliomas, AR immunoreactivity was more prevalent in astrocytomas than in 1p/19q codeleted oligodendrogliomas ( = 0.02). AR expression was associated with unmethylated MGMT promoter status ( = 0.02). DNA methylation analysis revealed AR gene hypomethylation in tumors displaying nuclear AR positivity and in IDH-wildtype GBMs (Kruskal-Wallis < 0.05). Additionally, methylation patterns of AR co-regulators located on the X chromosome suggest epigenetic regulation of AR signaling in gliomas. : The findings reveal distinct AR pathway activation patterns in adult-type diffuse gliomas, particularly IDH-wildtype GBMs, suggesting that further exploration of antiandrogen therapies is warranted. - Source: PubMed
Publication date: 2025/09/28
Gatto LidiaAsioli SofiaMorandi LucaDi Oto EnricoDi Nunno VincenzoTosoni AliciaAprile MartaBartolini StefaniaGriva LuciaMelotti SofiaGentilini FrancescaPinto GiuseppeCasadei FrancescoFoschini Maria PiaTonon CaterinaLodi RaffaeleFranceschi Enrico